Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors

Trial Profile

An open, multicenter phase II trial evaluating the antitumour efficacy of Faslodex (fulvestrant) in postmenopausal women with advanced breast cancer failing non-steroidal or steroidal aromatase inhibitors

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2007

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer; Menopause
  • Focus Therapeutic Use
  • Acronyms SAKK
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top